Regular ArticleImpact of recombinant soluble thrombomodulin (thrombomodulin alfa) on disseminated intravascular coagulation

IntroductionWe assessed the safety and effectiveness of recombinant soluble thrombomodulin (thrombomodulin alfa, TM-α) in the treatment of disseminated intravascular coagulation (DIC) in a post-marketing surveillance.MethodsThe cases of 3548 patients with DIC caused by infection (n = 2516, Infection-DIC) or hematological malignancy (n = 1032, Hemat-DIC) were analyzed and compared to the results of a phase III (P-III) study.ResultsThe DIC scores were significantly decreased in the Infection-DIC and Hemat-DIC groups with TM-α treatment (both P < 0.001). The incidences of critical bleeding adverse drug reactions (ADRs) in the Infection-DIC and Hemat-DIC groups were 2.6% and 2.4%, and the survival rates were 64.1% and 70.7%, respectively. Patients with DIC were subcategorized into three groups (Infection-DIC-1 or Hemat-DIC-1, P-III criteria-matched patients; Infection-DIC-2 or Hemat-DIC-2, P-III criteria-non-matched patients treated solely with TM-α; and Infection-DIC-3 or Hemat-DIC-3, P-III criteria-non-matched patients treated with TM-α and other concomitant anticoagulants). Subcategory analysis revealed that the incidences of critical bleeding ADRs of Hemat-DIC-2 and Hemat-DIC-3 were significantly higher and their survival rates were significantly lower than those of Hemat-DIC-1. By multivariate analysis in Hemat-DIC, younger age (odds ratio: 2.629, P = 0.0033) and pre-existing bleeding (odds ratio: 2.044, P = 0.019) were found to affect bleeding ADRs and the severity of underlying disease was the most important factor for survival rate (odds ratio: 0.288, P < 0.001).ConclusionsThis surveillance provided real-world data for the safety and effectiveness of TM-α in the treatment of Infection-DIC and Hemat-DIC in general practice settings.